Sudeep Pharma IPO Analyzed

Sudeep Pharma’s recent IPO saw strong investor interest, resulting in significantly more bids than shares offered. The IPO, which closed on November 25, 2025, was heavily subscribed, indicating confidence in the company’s future. This analysis breaks down the key details of the offering and provides insights for investors.

Key Points

• 99 crore shares bid, far exceeding the 1.05 crore shares offered.
• The IPO was 93.71 times subscribed, showing strong demand.
• Price band set at ₹563 – ₹593 per share for the fresh issue.
• ₹95 crore raised through a fresh issue, plus ₹800 crore offer for sale.
• Funds used for machinery and general corporate purposes.
• Strong promoter group ownership, at 89.36% of the pre-offer capital.

Sudeep Pharma specializes in making ingredients for medicines, food, and nutritional products. The company operates in two main areas: providing basic minerals like calcium and zinc, and developing advanced mineral systems for specific applications. This dual approach allows them to serve a diverse range of industries.

In the first quarter of the next fiscal year (Q1 FY26), around two-thirds of their revenue came from the pharmaceutical, food, and nutrition segment. The remaining third was generated by their specialty ingredients business, handled through their subsidiary, SNPL. This highlights the company’s diversified market reach.

Before the IPO, the company secured ₹268.49 crore from large investors – known as anchor investors – by selling 45.27 million shares at a price of ₹593 each. This pre-IPO funding demonstrated further investor confidence.

For the quarter ending June 30, 2025, Sudeep Pharma reported a healthy consolidated net profit of ₹30.81 crore and total sales of ₹124.92 crore. These results highlight the company’s financial stability and growth potential.

“This IPO represents a significant opportunity to invest in a growing company with a diverse product portfolio and a strong market position.”